Evaluation of commercial SARS-CoV-2 serological assays in Canadian public health laboratories.
Diagn Microbiol Infect Dis
; 101(3): 115412, 2021 Nov.
Article
in English
| MEDLINE | ID: covidwho-1201522
ABSTRACT
The COVID-19 pandemic has led to the influx of immunoassays for the detection of antibodies towards severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into the global market. The Canadian Public Health Laboratory Network Serology Task Force undertook a nationwide evaluation of twelve laboratory and 6 point-of-care based commercial serological assays for the detection of SARS-CoV-2 antibodies. We determined that there was considerable variability in the performance of individual tests and that an orthogonal testing algorithm should be prioritized to maximize the accuracy and comparability of results across the country. The manual enzyme immunoassays and point-of-care tests evaluated had lower specificity and increased coefficients of variation compared to automated enzyme immunoassays platforms putting into question their utility for large-scale sero-surveillance. Overall, the data presented here provide a comprehensive approach for applying accurate serological assays for longitudinal sero-surveillance and vaccine trials while informing Canadian public health policy.
Keywords
Full text:
Available
Collection:
International databases
Database:
MEDLINE
Main subject:
Serologic Tests
/
Public Health
/
SARS-CoV-2
/
COVID-19
/
Laboratories
/
Antibodies, Viral
Type of study:
Diagnostic study
/
Experimental Studies
/
Observational study
/
Prognostic study
Topics:
Vaccines
Limits:
Humans
Country/Region as subject:
North America
Language:
English
Journal:
Diagn Microbiol Infect Dis
Year:
2021
Document Type:
Article
Similar
MEDLINE
...
LILACS
LIS